内容概要：利尿药是一类能促进体内电解质和水分排出而增加尿量的药物。主要通过影响肾脏滤过、重 吸收和再分泌功能而发挥利尿作用。利尿剂在临床上常用于治疗心、肾、肝脏等疾病所引起的水肿，亦 用于高血压等非水肿性疾病的治疗。目前，我国心血管疾病的防治形势非常严峻，患者数量逐渐增多， 据《中国心血管健康与疾病报告2023》，中国CVD现患人数达3.3亿，其中心力衰竭（HF）890万、高 血压2.45亿。除此之外，随着老龄化人口的攀升，我国高血压、心衰、肾衰和肝硬化患者数量将不断增 加。利尿剂作为治疗高血压和心衰的重要药物，应用需求持续攀升，用药规模持续增长，2024年中国利 尿剂市场规模达42.2亿元，同比增长11%。医院端为利尿剂主要销售渠道，占比超过85%。2024年医院 端利尿剂销售规模为36.3亿元，同比增长13%，药店端为5.9亿元。我国利尿剂市场厂商数量众多，市场 竞争较为激烈，总体竞争格局较分散，同时本地药企品牌近几年已经牢牢占据了国内主要市场。2024年 前十家企业累计占据50%的市场份额，其余中小企业占据剩下的50%的市场份额。知名度较高，市场份 额较大的国内企业有桂林南药、天津力生制造、南京海辰药业 ...

小方制药主营业务一直专注于外用药领域，公司产品主要为非处方药品，品牌旗下的多种外用药产品： 开塞露、甘油灌肠剂、炉甘石洗剂、氧化锌软膏、水杨酸软膏、碘甘油、呋麻滴鼻液等产品市场占有率 处于国内领先地位。 以家庭常备外用药为经营核心的小方制药(603207)，将联合上海市皮肤病医院开发脱发新产品，这也意 味着公司正式切入中药复方制剂新药研发领域。 根据经营计划，储备产品管线及细化消费需求是关键环节之一。小方制药计划专注于家庭常备外用药细 分赛道，新产品管线研发储备紧紧围绕公司既定战略发展定位，拓展后续外用药的仿制及创新，充分利 用专家工作站平台的资源，优化后续产品研发结构，逐步健全外用药产品体系，覆盖更多的家庭健康外 用药应用需求。 小方制药近日与上海市皮肤病医院签署了《复方侧柏酊合作开发协议》，双方拟共同开展复方侧柏酊的 新药转化开发，该产品具有凉血行气和生发乌发的功效，主要用于治疗各型脱发。 小方制药表示，本次合作标志着公司以患者为中心、以临床价值为导向、正式切入中药复方制剂新药研 发，进一步扩宽了公司的发展赛道，丰富了公司产品管线布局。小方制药提示，本次签署协议暨开展新 产品开发预计不会对公司当期生产经营 ...

新华财经北京5月28日电（记者田晓航、戴小河）近日，国家药品监督管理局批准中药1.1类创新药小儿 牛黄退热贴膏上市。这一源自全国名中医临床经验方的中药新药获批上市，为急性上呼吸道感染风热证 所致的1至5岁发热儿童患者提供了新的治疗选择。 记者从有关部门了解到，2025年以来已有小儿黄金止咳颗粒、芪防鼻通片、复方比那甫西颗粒等多个中 药创新药获批上市，而2021年以来已有52个中药新药获批上市。中药新药上市步伐不断加快，如何看待 这一现象？ "中药新药获批上市数量显著增加，是中医药现代化与产业化进程加速的直观体现，背后是政策引导、 科研突破与临床需求的共振。"中国中医科学院西苑医院科研处副处长、主任医师付长庚说。 付长庚说，以西苑医院研发的 "麻荆宣肺颗粒" 为例，这一西苑医院呼吸科应用40多年的临床验方，有 望通过优化审评路径，加速转化为治疗感染后咳嗽的中药新药。 同时，在他看来，包括西苑医院在内的许多医疗及科研机构通过"临床－基础－转化"全链条创新，推动 了中药从"经验方改良"向"精准机制研究"转型，医院自主研发的新药通过现代药理学、系统生物学等技 术解析药效物质，提升了科学性；而产学研合作模式打通了"研发 ...

Group 1 - The article highlights the global concern over hypertension, with approximately 1.3 billion people affected, and emphasizes the severe challenge in China where only 16% of the 250 million hypertensive patients achieve treatment targets [1] - The combination of hypertension and dyslipidemia significantly increases the risk of cardiovascular diseases, making effective management of both conditions a key focus in the industry [1] - The introduction of a compound drug named "Duodayi" represents a new paradigm in the combined treatment of hypertension and dyslipidemia, addressing the shortcomings of previous treatment methods [1][3] Group 2 - The compound formulation combines amlodipine and atorvastatin, which are well-known and widely used medications for hypertension and dyslipidemia, respectively [2] - Pfizer's early patent application for the combination in 1998 laid the groundwork for the development of the world's first dual-action compound drug, which received FDA approval in 2004 and has since been recognized globally [2][6] - The drug "Caduet" (Duodayi) has been approved in over 70 countries and has become a significant player in the cardiovascular medication market [2][6] Group 3 - The single-tablet formulation improves patient adherence to treatment, with a reported 26% increase in the proportion of patients maintaining treatment over 12 months compared to taking two separate medications [4] - The dual-action drug has shown a significant improvement in achieving both blood pressure and lipid level targets compared to single medications or free combinations [6] Group 4 - In July 2021, Haizheng Pharmaceutical began local production of Duodayi, maintaining original drug quality while reducing adverse reactions and treatment costs by 25% compared to single medications [7] - The drug is available in multiple dosages, allowing for tailored treatment plans based on individual patient needs, enhancing treatment efficiency [7] Group 5 - Haizheng Pharmaceutical emphasizes quality control and has implemented a comprehensive management system to ensure high standards in production, achieving FDA certification [8] - The company has adopted a digital transformation strategy, integrating modern information technology with advanced manufacturing processes to enhance the entire lifecycle of drug production [8][9] Group 6 - Duodayi is positioned as a solution for chronic disease management, simplifying medication regimens for patients and showcasing the potential of local pharmaceutical innovation [9] - The success of Duodayi reflects the growth and evolution of the Chinese pharmaceutical industry, demonstrating that local production can match or exceed the quality of original formulations [9]